Hi Nikhil,

Agree with you nikhil that debt levels are too high. But, additional debt has been brought at a mere interest of 1-3%. TUFS benefit + Guj Govt benefit. Interest coverage ratio is high and that should comfort us. Out of total Interest cost of say 13% – company gets 5% subsidy from TUFS and 6% from Guj Govt. So net interest cost is 1-3%. We can buy this, since I feel it to be lot undervalued. Your views invited on this.

Best regards,
Abhishek shah.

pirmal phytocare core focus is
1 strong r&d
2.medicine derived from natural sources
3 bringing herbal medicine to the therapeutic forefront
4. strong cash balance with promoters after selling major pharmabusiness to abbot

below brief histroy about compny pl note that earlier sun pharmaadvance was also not in radar of anyone and this stock after strong accumlation now looking for better future
financial data not encouraging but it always follow after price increase so wish more input from others
holding since 1 year

Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.
PLSL is focused on four therapeutic areas – Cancer, Diabetes, Inflammation and Infectious Diseases. The company has a pipeline of fourteen compounds, including four in clinical trials. PLSL’s lead chemical compound, a Cdk-4 inhibitor, has completed two Phase I studies and is being tested in another Phase I/II trial for Multiple Myeloma. PLSL has drug discovery and development agreements with Eli Lilly & Company and Merck & Company, two of the leading pharmaceutical companies in the world.
PLSL has been listed on the National Stock Exchange and the Bombay Stock Exchange since June 2008.
PLSL partners with leading Indian educational institutes to form a research collaborations namely Anna University, Chennai, Indian Institute of Science, Bangalore, Regional Research Laboratory, Jammu, Central Drug Research Institute, Lucknow, National Institute of Immunology, Delhi, National Institute of Oceanography, Goa, and Indian Institute of Chemical Biology, Kolkata.
The company has fourteen compounds in pipeline that includes four in clinical trials. PLSL’s lead chemical compound a Cdk-4 inhibitor has successfully completed two phase studies and will be tested in another Phase I/II trials.
The company has a number of molecules in its research pipeline – in oncology (biological targets: Cyclin Dependent Kinase Cell Cycle inhibitors, Hypoxia Inducible Factor-1a (HIF-1a) Inhibitors, PI3 Kinase Inhibitors), inflammation (TNF – Production / Release Inhibitors, Safer NSAIDs), diabetes (Insulin Sensitizers [non-PPAR], GPR40 Modulators) and infectious disease (Microbial extracts: Antibacterial, Microbial extracts: Antifungal). PLSL also has a comprehensive library of plant extracts and microbial strains.
Research Activities
The company’s research vision and strategy is based on three core principles:Provide scientists state-of-the-art infrastructure to produce world-class science. Leverage India’s bio-diversity and wealth of knowledge on traditional systems of medicines to source drug lead molecules. And collaborate with academic institutions. Following are the research activities:
Molecular Biology
Biomarker Discovery
Medicinal and Synthetic Chemistry
Polymer Chemistry
Analytical Chemistry
Natural Products
Herbal Extraction
HTS Group
Oncology
Inflammation
Diabetes
Vaccine
Special Projects
Clinical Development
Business Development
In-vivo Pharmacology
Discovery Informatics
Awards & Achievements
Dr. Somnath Halder, Group Leader – Medicinal Chemistry, Piramal Life Sciences Limited, wins InnoCentive award for a novel idea to solve a Synthetic Ideation Challenge for an efficient synthesis of vinyl glycine or its hydroxy analogue
Dr. Kalpana Joshi, Vice President – Target identification, Piramal Life Sciences Limited, wins the ‘Lokmat Maharashtrian of the Year’ award for Science and Technology.
Milestones
2008
The company gets listed in the NSE and BSE
The company entered into a collaboration agreement with Pierre Fabre Laboratories for research in oncology
The company made an oral presentation during the 68th Scientific Session of the American Diabetes Association (ADA) being convened at San Francisco, California, USA. The presentation was on preclinical pharmacological data pertaining to a novel, orally active glucose-lowering compound, P1736, discovered and developed at Piramal Life Sciences, Mumbai, using their proprietary insulin resistance cell model.
Industry-University/National institutes partnership, were industry and academia will work together to screen such a large number of bacterial isolates. Different academic institutes will isolate organisms’ specific to diverse ecological niches.
The company received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada.
The company received regulatory approval for the initiation of a phase-I study in India by Drug Controller General of India (DCGI) of a new cancer compound, P-1446A-05.
The company started its Phase II trial of P276 for head and neck cancer
2009
The company started phase II trial in USA for its lead cancer compound P 276-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.
The company received regulatory approval by Drug Controller General of India (DCGI) for the initiation of two phase-I/II combination studies of its cancer molecule P276 for pancreatic and head and neck cancer.
The company commenced Phase I trial of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.
The company completed Phase I Trials with a New Molecule for Type II Diabetes in Europe
The company made a presentation during the 49th Scientific Session of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being convened at San Francisco, California, USA
2010
The company introduced Tinefcon, its newly developed natural remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA
2011
The Department of Biotechnology (DBT), Government of India and Piramal Life Sciences Limited (PLSL) have begun Phase II of their Drug Discovery Public Private Partnership to find new drugs from 14000 bioactive cultures discovered in a nationwide search for new drugs from biodiverse habitats across the country in collaboration with 9 national institutes.

I dont think it would have such a severe impact as they have been procuring seeds from various geographies and not just Tamil Nadu.

I no more hold NDL but here are my two cents.

Dolly khanna’s purchasing price is most probably from 60+ levels as I had purchased the stock before any big name was involved with the company. If I recall correctly, DK first appeared in the SHP in march 2015.

The big issue here is the debt levels. Also the business is quite capital intensive. One can own it purely on basis of growth potential but expecting rerating from these levels seems a little far fetched.

Disclosure:- held NDL in the past from 57 levels. Booked around 170 levels. Do not consider this as a recommendation to buy/sell